Science Hub
The Science of Microdosing
Microdosing sits at the intersection of psychopharmacology, neuroscience, and behavioural research. This hub covers what the evidence actually says: mechanisms, protocols, outcomes, and the honest limits of what is currently known.
peer-reviewed studies published since 2018
active trial institutions: Imperial College, Johns Hopkins, NYU, UCSF
primary outcome areas studied: mood, cognition, and neuroplasticity
The Science Hub is open. Whether you are a practitioner evaluating protocols, a researcher exploring entourage methodology, or simply curious about the mechanisms behind the practice, this research library requires no membership, no login, and no commitment. Evōke publishes its scientific reasoning openly as a matter of principle.
Sub-Perceptual. Intentional. Measurable.
Microdosing refers to the practice of consuming sub-perceptual doses of a psychedelic substance, typically psilocybin, at regular intervals. The dose is intentionally set below the threshold for hallucinogenic effects: roughly one-tenth to one-twentieth of a full dose. At this level, most people report no perceptual distortion, no impairment of daily function, and no altered state in the traditional sense.
The practice is not new. Researchers began documenting anecdotal reports in the 1960s, and James Fadiman's 2011 work on psychedelic protocols helped formalise the concept for a modern audience. What has changed significantly in the past decade is the research infrastructure surrounding it: clinical trials at Imperial College London, Johns Hopkins University, NYU, and UCSF have begun producing peer-reviewed data on mechanisms, outcomes, and safety profiles.
"A microdose is sub-perceptual: small enough to leave ordinary functioning intact, large enough to engage the mechanisms researchers are now actively studying."
How Microdosing Works
Three Mechanisms That Appear Consistently in the Research
Three primary biological pathways appear consistently in the research literature. These are not speculative. Each has been observed in controlled studies and replicated across multiple research groups.
Serotonin Receptor Agonism
5-HT2A · Prefrontal Cortex · DMN Modulation
Psilocybin's primary mechanism involves agonism at the 5-HT2A serotonin receptor, expressed densely in the prefrontal cortex, the region governing executive function, planning, and emotional regulation. At sub-perceptual doses, this interaction appears to modulate default mode network activity without the full pattern-disruption seen at higher doses.
A 2023 study in Neuropsychopharmacology found measurable 5-HT2A binding changes at doses as low as 0.1mg psilocybin.
BDNF Upregulation & Neuroplasticity
Brain-Derived Neurotrophic Factor · Synaptic Growth · LTP
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival and growth of neurons and the formation of new synaptic connections. Psychedelics, including at sub-perceptual doses, have been shown to upregulate BDNF expression. This is the same pathway targeted by many antidepressant compounds, and one reason researchers have begun examining microdosing as a potential adjunct to conventional mental health treatment.
Imperial College London's 2022 psilocybin trial documented BDNF increases in participants receiving low-dose protocols.
Default Mode Network Modulation
DMN Suppression · Rumination · Cognitive Flexibility
The default mode network (DMN) is a set of brain regions active during self-referential thinking, mind-wandering, and rumination. Overactivity in the DMN is associated with depression, anxiety, and rigid thinking patterns. Neuroimaging studies show that even low doses of psilocybin reduce DMN connectivity, temporarily loosening habitual thought patterns without inducing a full psychedelic state.
Carhart-Harris et al. (2012, PNAS) established this mechanism; subsequent work has extended the finding to sub-hallucinogenic doses.
Three Outcome Areas. Honest Assessment.
The evidence base for microdosing is growing, but it is uneven. Some findings are replicated across independent studies; others rest on self-report data with known methodological limitations. The distinction matters. Here is where each outcome area currently stands.
Mood & Emotional Wellbeing
The largest self-report study to date, Szigeti et al. (2021, eLife), followed 191 microdosers and 191 controls over four weeks. Microdosers reported small-to-medium improvements in mood, focus, and wellbeing. Critically, expectation effects accounted for some but not all of the observed benefit.
Szigeti et al. (2021), eLife · Imperial College London
Cognitive Performance
A 2019 study by Prochazkova et al. found improvements in convergent and divergent thinking tasks in participants who self-administered a single microdose. The effect was observed 4 hours post-dose. Sample size was small (36 participants), and the researchers noted the absence of placebo control as a key limitation.
Prochazkova et al. (2019), Psychopharmacology
Depression
Carhart-Harris et al. compared psilocybin therapy to escitalopram in treatment-resistant depression, finding psilocybin non-inferior on primary outcome measures and superior on several secondary measures including emotional processing. While this trial used full doses, not microdoses, it established the mechanistic framework that informs current low-dose research.
Carhart-Harris et al. (2021), NEJM
Neuroplasticity & Structural Change
Animal studies document measurable structural synaptic changes, including dendritic spine growth and BDNF upregulation, within hours of psilocybin administration, persisting for days to weeks. Human neuroimaging studies confirm DMN suppression and increased neural entropy at sub-perceptual doses.
Ly et al. (2018), Cell Reports · Carhart-Harris et al. (2014), Frontiers
Long-term safety profiles beyond six months. Optimal dosing protocols across different populations. Interaction effects with existing medications. Whether observed benefits persist after discontinuation. These are open questions, and honest acknowledgement of them is part of what distinguishes credible research communication from marketing.
Protocols
What the Research Uses
The protocols studied in research settings vary in dosing frequency, dose size, and rest periods. Three appear most consistently in the literature and in structured self-report studies.
The Fadiman Protocol
James Fadiman · The Psychedelic Explorer's Guide (2011) Day / Rest / Rest / RepeatEvery third day. Designed to minimise tolerance buildup while maintaining consistent effect. The two rest days allow neurological reset. Most widely studied protocol in citizen science and academic observational research. The standard reference point for most microdosing discourse.
The Stamets Stack
Paul Stamets, mycologist · ongoing trials 4 Days On / 3 Days OffCombines psilocybin with Lion's Mane mushroom and Niacin. Lion's Mane (NGF stimulation) and Niacin (peripheral nervous system activation) are hypothesised to enhance neuroplasticity through pathways independent of 5-HT2A. Clinical evidence for the combination is preliminary but mechanistically coherent.
Every Other Day
Used in some clinical trial designs Day / Rest / Day / RestHigher frequency than Fadiman. Some researchers prefer this for consistency of effect; others note greater tolerance risk. Suitable for closely monitored research settings. Less common in self-directed practice due to tolerance concerns at higher frequency.
The protocols described here are drawn from published research and observational studies. Evōke does not prescribe or recommend specific protocols. This content is for informational purposes only and does not constitute medical advice. Protocol guidance for members is available in the member resource library. Consult a qualified healthcare provider before making any changes to your health regimen.
Six Topics. One Complete Picture.
These six research areas are not independent topics. They are the interconnected components of a complete scientific account of how precision microdosing works and why it is designed the way it is. Neuroplasticity explains the mechanism that makes change possible. Consolidation explains how that change is stabilised. Mood and cognition map the outcomes the research has studied. Full spectrum extraction explains why the formulation method matters. Protocol design closes the loop, connecting mechanism to practice.
Reading all six gives you the full picture. Each page stands alone, but they are written to build on one another. The sequence below is the logical order.
"The mechanisms on these pages are the same ones that inform how Evōke approaches protocol design, formulation, and outcome measurement. The science is public. The application is a member benefit."
Neuroplasticity & the Opening Mechanism
How psilocybin creates the neurological conditions for change: BDNF upregulation, DMN suppression, cortical entropy, and the structural basis of the plasticity window. The foundational mechanism everything else builds on.
5-HT2A · BDNF · DMN · Synaptic Growth Cluster 2Consolidation & the GABA-A System
Muscimol's mechanism, the consolidation hypothesis, and why GABAergic modulation after a plasticity window has mechanistic rationale grounded in memory consolidation research. The second compound in the entourage stack.
Muscimol · GABA-A · Memory Consolidation · Amanita Cluster 3Mood & Emotional Regulation
The serotonergic basis of mood regulation, how sub-perceptual psilocybin differs mechanistically from SSRIs, and where the clinical evidence on depression and emotional processing currently stands.
Serotonin · 5-HT2A · DMN · Depression Research Cluster 4Focus & Cognitive Performance
What the research shows about attention, executive function, and creative problem-solving at sub-perceptual doses, and why the cognitive mechanism differs qualitatively from stimulant-class enhancement.
Neural Entropy · DMN · BDNF · LTP Cluster 5Full Spectrum Extraction & Delivery
Why extraction method and delivery format are as pharmacologically significant as the compound itself: the entourage principle applied to psilocybin, honey matrix pharmacokinetics, and the honest case for full spectrum over isolated compounds.
Entourage Effect · Bioavailability · Alkaloid Profile · Honey Matrix Cluster 6Designing for an Outcome
The precision approach: starting with a neurological target, identifying the mechanisms relevant to that target, and selecting compounds and timing accordingly. The public framework behind Evōke's formulation logic.
Protocol Design · Compound Mapping · Timing · IntegrationEvōke Is Designed Around What the Evidence Shows.
The mechanisms across these six pages, 5-HT2A engagement, BDNF upregulation, DMN modulation, GABA-A consolidation, entourage extraction, are the same ones that inform how Evōke approaches formulation, protocol guidance, and outcome documentation. The science hub is not a marketing exercise. It is the reasoning made public, so that members and practitioners can evaluate it on its own terms.
Request Membership